ArticleBrain : a journal of neurology2025
Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma.
Article in Brain : a journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Cellular hallmarks and aging clock of the human lung parenchyma.Nature communications · 2026Article
- Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy.MedComm · 2026Review
- Astrocyte-driven immunosuppression in the brain tumor microenvironment.Nature immunology · 2026Review
- A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma.Nature cancer · 2025Article
- Learning the cellular origins across cancers using single-cell chromatin landscapes.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Glioblastoma is the most aggressive and lethal adult brain tumour. The cellular heterogeneity within the tumour microenvironment plays a crucial role in the complexity of treatment and poor survival. Glioblastoma is typically classified into three molecular subtypes (classical, mesenchymal and proneural) associated with EGFR, NF1 and PDGFRA genetic drivers, respectively. Yet, the role of these driver mutations in the glioblastoma tumour microenvironment is not fully understood. Here, we used single-cell RNA sequencing of genetically engineered mouse glioblastoma models incorporating human-relevant EGFRvIII, PDGFB and NF1 driver mutations to characterize the genotype-immunophenotype relationship of the three glioblastoma subtypes systematically. Murine genetic glioblastoma models at the single-cell level effectively mimic the inter- and intra-tumour heterogeneity found in human counterparts. Our analysis revealed that PDGFB-driven tumours were more proliferative and enriched for Wnt signalling interactions, whereas EGFRvIII-driven tumours showed an elevated interferon signalling response. Moreover, Nf1-silenced tumours displayed higher myeloid abundance, myeloid immunosuppressive interactions involving Spp1, regulatory T-cell infiltration and expression of immune checkpoint molecule Ctla4. Overall, we established a human-mouse analytical platform for genotype-aware target discovery and validation, which offers promising new avenues for more effective, personalized treatments in glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.